Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2019 2
2020 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.
Goto H, Hidaka D, Yamamoto S, Hayasaka K, Michimata R, Kagawa I, Sunagoya K, Iijima H, Hayase E, Shiratori S, Okada K, Sugita J, Onozawa M, Hashimoto D, Kahata K, Fujimoto K, Endo T, Shimizu C, Teshima T; North Japan Hematology Study Group (NJHSG). Goto H, et al. J Clin Apher. 2020 Sep;35(5):413-419. doi: 10.1002/jca.21816. Epub 2020 Jul 29. J Clin Apher. 2020. PMID: 33043486
Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Shiratori S, Ohigashi H, Takahashi S, Ara T, Goto H, Nakagawa M, Sugita J, Onozawa M, Kahata K, Endo T, Hashimoto D, Teshima T; North Japan Hematology Study Group (NJHSG). Shiratori S, et al. Ann Hematol. 2020 Mar;99(3):591-598. doi: 10.1007/s00277-020-03937-3. Epub 2020 Feb 1. Ann Hematol. 2020. PMID: 32006152 Clinical Trial.
Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Shiratori S, Kosugi-Kanaya M, Shigematsu A, Kobayashi H, Yamamoto S, Kobayashi N, Iwasaki H, Mori A, Kunieda Y, Yutaka T, Kurosawa M, Kakinoki Y, Endo T, Kondo T, Hashino S, Teshima T; North Japan Hematology Study Group (NJHSG). Shiratori S, et al. Leuk Lymphoma. 2015;56(9):2592-7. doi: 10.3109/10428194.2014.1001985. Epub 2015 Feb 24. Leuk Lymphoma. 2015. PMID: 25563559
Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
Kondo T, Fujioka M, Fujisawa S, Sato K, Tsuda M, Miyagishima T, Mori A, Iwasaki H, Kakinoki Y, Yamamoto S, Haseyama Y, Ando S, Shindo M, Ota S, Kurosawa M, Ohba Y, Teshima T; North Japan Hematology Study Group (NJHSG). Kondo T, et al. Int J Hematol. 2019 Oct;110(4):482-489. doi: 10.1007/s12185-019-02696-w. Epub 2019 Jun 25. Int J Hematol. 2019. PMID: 31240558 Clinical Trial.
Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.
Senjo H, Kanaya M, Izumiyama K, Minauchi K, Hirata K, Mori A, Saito M, Tanaka M, Iijima H, Tsukamoto E, Itoh K, Ota S, Morioka M, Hashimoto D, Teshima T; North Japan Hematology Study Group (NJHSG). Senjo H, et al. Cancer Med. 2019 Mar;8(3):953-962. doi: 10.1002/cam4.1973. Epub 2019 Feb 20. Cancer Med. 2019. PMID: 30790452 Free PMC article.